SKYE BIOSCIENCE INC (SKYE) Stock News

NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD

3.25 -0.26 (-7.41%)

After market: 3.27 +0.02 (+0.62%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SKYE Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: The Motley Fool

Skye (SKYE) Q2 R&D Soars 249% No Revenue

6 days ago - By: Skye Bioscience, Inc.

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

6 days ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

14 days ago - By: Skye Bioscience, Inc.

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

a month ago - By: Yahoo Finance - Mentions: HROW

William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating

3 months ago - By: Benzinga - Mentions: MSC ELUT ACIW JYNT ...

Earnings Scheduled For May 8, 2025

2 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

2 months ago - By: Yahoo Finance - Mentions: PYPD

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

2 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

3 months ago - By: Zacks Investment Research - Mentions: NVO LLY CRBP

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming Investment Conferences

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

4 months ago - By: Skye Bioscience, Inc.

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

5 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

6 months ago - By: Skye Bioscience, Inc.

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Participate in SXSW Session on Obesity

6 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Present at TD Cowen Health Care Conference

6 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Announces Participation in February Conferences